Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Published:2009-03-12 Issue:6 Volume:23 Page:1054-1061
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hochhaus A, ,O'Brien S G,Guilhot F,Druker B J,Branford S,Foroni L,Goldman J M,Müller M C,Radich J P,Rudoltz M,Mone M,Gathmann I,Hughes T P,Larson R A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200938.pdf

Reference30 articles.

1. Goldman JM, Melo JV . Chronic myeloid leukemia––advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1464.

2. Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172–183.

3. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189–218.

4. Van Etten RA . Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004; 28 Suppl 1: S21–S28.

5. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG . BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179–1187.

Cited by 731 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An exceptional case of imatinib mesylate inducing both psoriasis and lichenoid reaction: A case report;Journal of Cutaneous Pathology;2024-08-20

2. Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety;Meditsinskiy sovet = Medical Council;2024-07-25

3. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04

4. JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib;Disease Markers;2024-04-12

5. Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?;Expert Review of Clinical Pharmacology;2024-02-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3